OncoMatch

OncoMatch/Clinical Trials/NCT07332455

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Is NCT07332455 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies GSK5471713 for neoplasms, prostate.

Phase 1/2RecruitingGlaxoSmithKlineNCT07332455Data as of Jun 2026Location: United States · Canada

Treatment: GSK5471713 — This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

GSK5471713

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Male only

Prior therapy

Must have received: androgen deprivation therapy

prostate cancer progression while on Androgen deprivation therapy (ADT)

Must have received: androgen receptor pathway inhibitor — Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC)

progression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC)

Must have received: taxane

received 1-2 prior taxane based chemotherapy regimens

Cannot have received: androgen receptor degrader

Prior therapy with Androgen receptor (AR) Degrader targeted therapy

Lab requirements

Cardiac function

Impaired cardiac function or clinically significant cardiac disease [excluded]

Impaired cardiac function or clinically significant cardiac disease

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • GSK Investigational Site · Grand Rapids, Michigan
  • GSK Investigational Site · West Valley City, Utah

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07332455 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior androgen receptor degrader disqualifies patients from enrollment.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify